BeiGene, Ltd. (NASDAQ:BGNE) Research Coverage Started at Ladenburg Thalmann Financial Services

Paterniano Del Favero
Agosto 12, 2017

Zacks Investment Research upgraded BeiGene from a "sell" rating to a "buy" rating and set a $79.00 target price on the stock in a research note on Tuesday, July 11th. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, based in Camana Bay, Cayman Islands.

A number of brokerages recently commented on BGNE. Maxim Group lifted their price target on shares of BeiGene from $57.00 to $73.00 and gave the stock a buy rating in a research note on Friday, July 7th. Morgan Stanley reissued an overweight rating and set a $83.00 price target on shares of BeiGene in a research note on Monday, July 10th. Finally, Robert W. Baird lifted their price objective on BeiGene from $44.00 to $58.00 and gave the company an "outperform" rating in a report on Thursday, July 6th.

Ladenburg Thalmann Financial Services began coverage on shares of BeiGene, Ltd. (NASDAQ:BGNE) in a research report report published on Monday, Marketbeat reports. The company presently has a consensus rating of Buy and a consensus target price of $74.80. The stock now has an average rating of "Buy" and an average price target of $74.80.

The original version of this article can be accessed at The stock had a trading volume of 770,293 shares.

The firm's market cap is $3.07 billion. The company traded as high as $79.40 and last traded at $79.28, with a volume of 99,150 shares. The company has a 50 day moving average price of $67.27 and a 200-day moving average price of $45.56. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and global trademark and copyright laws.

In other BeiGene news, CEO John Oyler sold 98,500 shares of the company's stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $44.16, for a total transaction of $4,349,760.00. Following the completion of the sale, the director now directly owns 55,000 shares of the company's stock, valued at $2,200,000.

On Wednesday, June 28th, Xiaodong Wang sold 35,000 shares of BeiGene stock. The shares were sold at an average price of $40.00, for a total value of $221,560.00. Following the completion of the transaction, the chief executive officer now owns 88,535 shares in the company, valued at approximately $3,909,705.60. Donald W. Glazer, Director disclosed the sale of 10,810 shares of (BGNE). One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company.

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in BeiGene during the first quarter worth about $238,000. Airain ltd purchased a new stake in BeiGene during the first quarter worth $320,000. Finally, ProShare Advisors LLC increased its stake in BeiGene by 42.0% in the first quarter. Ariose Capital Management Ltd now owns 198,609 shares of the company's stock valued at $7,271,000 after buying an additional 160,010 shares during the last quarter. Institutional investors own 43.85% of the company's stock.

Including today's unusual volume, BeiGene, Ltd.'s stock is performing at 133.93% on the year. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer.

Altre relazioni OverNewsmagazine

Discuti questo articolo